Doctors in Denial: Why Big Pharma and the Canadian medical profession are too close for comfort

Front Cover
James Lorimer & Company, May 1, 2017 - Business & Economics - 344 pages

Doctors in Denial examines the relationship between the Canadian medical profession and the pharmaceutical industry, and explains how doctors have become dependents of the drug companies instead of champions of patients' health. Big Pharma plays a role in every aspect of doctors' work. These giant, wealthy multinationals influence how medical students are trained and receive information, how research is done in hospitals and universities, what is published in leading medical journals, what drugs are approved, and what patients expect when they go into their doctors' offices. But almost all doctors deny the influence and control the drug companies exert. In this book Dr. Lexchin urges the medical profession to make the changes needed to give priority to protecting and promoting patients' health and benefitting society, rather than enabling Big Pharma to dominate health care while raking in billions in profits from citizens and governments.

 

Contents

Tables Figures and Boxes
7
Abbreviations
9
Foreword
11
welcome to the comfort zone
19
a marriage of convenience or a marriage made in heaven?
31
ménage à trois
43
Chapter 3 Medical journals advertisements money regulation rebellion and possibly retrenchment
65
research money controversies conflict of interest and independence
97
a guide to salvation?
149
get them while they are young
182
Chapter 8 Doctors sales representatives samples gifts trips and dinners
206
Chapter 9 Dont worry be happy?
233
Chapter 10 Reforming the comfort zone so that doctors are no longer in denial
251
Acknowledgements
291
References
296
Index
338

getting the message out
124

Other editions - View all

Common terms and phrases

About the author (2017)

Joel Lexchin is an internationally-recognized expert in pharmaceutical policy. He received his MD from the University of Toronto in 1977 and has spent over thirty years working as an emergency physician in Hamilton and Toronto. He is a Professor Emeritus in the School of Health Policy and Management at York University where he taught health policy from 2001 to 2016. He has been an advocate for change in pharmaceutical policy for thirty-five years, has appeared before numerous parliamentary committees, and has authored or co-authored over 150 articles about all aspects of how medicines are developed and used. His most recent book Private Profits versus Public Policy: The Pharmaceutical Industry and the Canadian State was published in early 2016.

Bibliographic information